DVT Interventional Management (SVS/AVF 2020)
DVT Interventional Management (SVS/AVF 2020): Acute DVT - Consider Intervention → DVT Extent Assessment → Clinical Severity → Phlegmasia Cerulea Dolens ...
Interactive Decision Tree
Algorithm Steps
- ▶Start
Acute DVT - Consider Intervention
Iliofemoral DVT confirmed, within 14-21 days of symptom onset
- ◆Decision
DVT Extent Assessment
Iliofemoral vs isolated femoropopliteal
- Iliofemoral: common femoral and/or iliac involvement
- Femoropopliteal only: less likely to benefit from intervention
- Confirm with ultrasound ± CT/MR venography
- Assess for May-Thurner syndrome (iliac compression)
- ◆Decision
Clinical Severity
Assess limb-threatening features
- Phlegmasia alba dolens: massive edema, pale limb
- Phlegmasia cerulea dolens: venous gangrene risk, cyanotic
- Severe symptoms: significant swelling, functional impairment
- Young, active patient with good life expectancy
- ⚠Warning
Phlegmasia Cerulea Dolens
EMERGENCY - limb-threatening
- Immediate anticoagulation (UFH)
- Urgent thrombus removal
- Surgical thrombectomy or CDT/PMT
- May require fasciotomy
- High morbidity/mortality without treatment
- ●Action
Surgical Thrombectomy
Open or hybrid approach
- Rarely first-line now
- Consider for: phlegmasia, failed CDT/PMT
- Groin incision, femoral venotomy
- Balloon catheter thrombectomy
- May combine with endovascular stent
- ●Action
Iliac Vein Stenting
For underlying stenosis/May-Thurner
- IVUS to assess residual stenosis
- May-Thurner: >50% compression common
- Dedicated venous stent (Wallstent, Venovo, Abre)
- Extend into common femoral if needed
- Reduces rethrombosis risk
- ●Action
Post-Intervention Management
Anticoagulation and surveillance
- Continue anticoagulation (3+ months)
- Compression therapy (graduated stockings)
- Duplex surveillance at 1, 3, 6, 12 months
- Monitor for stent patency if stented
- Activity: early ambulation encouraged
- ✓Outcome
Successful Thrombus Removal
Reduced symptom severity; may reduce PTS risk in iliofemoral DVT
- ✓Outcome
Post-Thrombotic Syndrome Risk
PTS develops in 20-50% of DVT patients; intervention may reduce severity
- ✓Outcome
Bleeding Complication
Major bleeding 2-4% with CDT; lower with PMT
- ●Action
Pharmacomechanical Thrombectomy (PMT)
Combined mechanical + pharmacological
- AngioJet, ClotTriever, FlowTriever devices
- Single session treatment
- Less thrombolytic needed
- Lower ICU requirement
- Growing preference over CDT alone
- ◆Decision
Intervention Candidacy
Patient selection for early thrombus removal
- Symptom duration <14-21 days
- Good functional status
- Low bleeding risk
- Life expectancy >2 years
- Patient preference (shared decision-making)
- ◆Decision
Contraindications to Intervention
Bleeding risk assessment
- Active bleeding
- Recent major surgery (<10 days)
- Recent stroke (<3 months)
- Intracranial pathology
- Severe thrombocytopenia
- Pregnancy (relative)
- ●Action
Catheter-Directed Thrombolysis (CDT)
Infusion catheter with tPA
- Popliteal or tibial access
- Multi-sidehole catheter through thrombus
- tPA 0.5-1 mg/hr infusion
- ICU monitoring during infusion
- Serial venography to assess progress
- Duration 12-48 hours typically
- ⚠Warning
IVC Filter
Only if anticoagulation contraindicated
- NOT routine with anticoagulation
- Only if absolute AC contraindication
- Retrievable filter preferred
- Plan for retrieval when AC safe
- Consider if large free-floating thrombus + high PE risk
- ●Action
Anticoagulation Only
For patients not candidates for intervention
- DOAC preferred (rivaroxaban, apixaban)
- LMWH if cancer-associated
- Duration: minimum 3 months
- Compression stockings (patient preference)
- Early mobilization
Guideline Source
SVS/AVF Clinical Practice Guidelines for Iliofemoral DVT Early Thrombus Removal
Clinical Safety Information
Clinical Decision Support — Not a Substitute for Clinical Judgment
Individual patient factors may require deviation from these recommendations.
Known Limitations
- ATTRACT trial showed CDT didn't reduce PTS at 24 months overall
- Iliofemoral DVT subgroup may still benefit from intervention
- Requires specialized vascular intervention capability
- Patient selection critical - not all DVTs benefit
- May-Thurner syndrome should be assessed and treated
Contraindicated Populations
Applicable Regions
EU: ESVS guidelines similar, emphasis on patient selection
US: SVS/AVF 2020 guidelines; selective approach post-ATTRACT
Next steps
Finish the workflow by opening the most relevant calculator, then convert the session into a live account when you are ready.
Related Resources
Frequently Asked Questions
What is the DVT Interventional Management (SVS/AVF 2020)?
The DVT Interventional Management (SVS/AVF 2020) is a management clinical algorithm for Vascular Surgery. It provides a structured decision tree to guide clinical decision-making, based on SVS/AVF Clinical Practice Guidelines for Iliofemoral DVT Early Thrombus Removal.
What guideline is the DVT Interventional Management (SVS/AVF 2020) based on?
This algorithm is based on SVS/AVF Clinical Practice Guidelines for Iliofemoral DVT Early Thrombus Removal (DOI: 10.1016/j.jvs.2020.04.518).
What are the limitations of the DVT Interventional Management (SVS/AVF 2020)?
Known limitations include: ATTRACT trial showed CDT didn't reduce PTS at 24 months overall; Iliofemoral DVT subgroup may still benefit from intervention; Requires specialized vascular intervention capability; Patient selection critical - not all DVTs benefit; May-Thurner syndrome should be assessed and treated. Individual patient factors may require deviation from these recommendations.
Get AI-Powered Analysis Alongside This Algorithm
In AttendMe.ai, the DVT Interventional Management (SVS/AVF 2020) appears automatically when your clinical question matches — alongside evidence from 3M+ peer-reviewed articles.
Try AttendMe Free